Welltower (WELL) Q4 2025 earnings review
Welltower 3.0: A High-Speed Transformation
Welltower closed FY25 with a transformative quarter that reshaped the company. Q4 normalized FFO rose 28% YoY to $1.45/share, capping a year of 22.5% growth. The headline story is the massive capital rotation: the company deployed $13.9 billion in acquisitions (primarily UK Senior Housing) while disposing of $7.5 billion in assets (exiting the lower-growth Outpatient Medical business). Operational metrics remain elite, with Seniors Housing Operating (SHO) SSNOI growing 20.4%. FY26 guidance projects continued momentum with FFO rising another ~17% at the midpoint.
🐂 Bull Case
The Seniors Housing Operating (SHO) portfolio posted its 12th consecutive quarter of >20% Same Store NOI growth (20.4%). With 400bps of occupancy gain and 4.7% RevPOR growth, the pricing power thesis remains intact.
By swapping lower-growth Outpatient Medical (OM) assets for high-growth Seniors Housing (via the Barchester and HC-One deals), the company has structurally increased its long-term growth rate.
🐻 Bear Case
Welltower absorbed $13.9 billion in new investments in a single quarter. Integrating operations of this magnitude (UK expansion, new RIDEA structures) creates significant execution risk in FY26.
GAAP administrative expenses exploded to $1.56 billion in Q4 (vs $49M prior year) due to the new 'Executive Continuity' stock plan. While normalized out of FFO, this is a massive shareholder cost that creates noise in the financials.
⚖️ Verdict: 🟢🟢
Strong Buy. Welltower is aggressively capitalizing on the 'Silver Tsunami.' The strategic pivot from Medical Office to pure-play Senior Housing is timed perfectly with demographics. 28% FFO growth and record-low leverage (3.03x) justify the premium.
Key Themes
The Great Portfolio Rotation
Welltower executed a massive strategic pivot in Q4. They sold $5.2B of the Outpatient Medical (OM) portfolio (part of a $7.2B total exit) and reinvested $13.9B, primarily into UK senior housing (Barchester and HC-One). This moves the company 'All-In' on the higher-growth B2C senior housing sector. The deal velocity is staggering.
Seniors Housing Pricing Power
The core engine remains red-hot. SHO Same Store NOI grew 20.4%, driven by a combination of 400 bps occupancy gains and 4.7% pricing (RevPOR) growth. Crucially, SSNOI margin expanded 270 bps, proving that revenue gains are falling to the bottom line faster than expenses are rising.
Administrative Expense Explosion
Investors looking at GAAP Net Income will see a confusing drop to $0.14/share despite the boom. This is due to a massive $1.56 billion G&A charge (up from ~$49M typically) linked to the new 'Executive Continuity Program.' While this is 'normalized' out of FFO, it represents a significant dilution event via stock comp for management (CEO + 11 execs) over the next decade.
Fortress Balance Sheet
Despite the massive $13.9B acquisition volume, Welltower actually *deleveraged*. Net Debt to Adjusted EBITDA fell to 3.03x (down from 3.49x a year ago), thanks to $7.5B in dispositions and equity raises. This gives them immense dry powder ($10.2B liquidity) for further opportunism in FY26.
Private Funds Business Launch
Welltower closed its first private fund ('Seniors Housing Fund I') with $2.5B in commitments, anchored by ADIA. This marks the start of a capital-light asset management income stream, diversifying revenue sources beyond direct rents.
Other KPIs
Accelerating. Up 28.3% YoY, accelerating from the 20-22% growth rates seen earlier in the year. The scaling of the SHO portfolio is generating massive operating leverage.
Stable/High. Margins continue to expand as occupancy fills up. The 'Welltower Business System' (tech platform) appears to be keeping expense growth (ExpPOR) well below revenue growth.
Decelerating (Improving). Down from 3.49x in 24Q4 and 12.9x in 2020. This is an extraordinarily low leverage profile for a REIT growing this fast, reducing interest rate risk.
Guidance
Accelerating (Absolute Terms). The midpoint of $6.17 implies a $0.88 per share increase (+16.6%) over FY25. While the *percentage* growth is lower than FY25's 22%, the absolute dollar value creation is higher. This assumes no unannounced acquisitions.
Stable. The range brackets the 20.4% achievement in Q4 25. Management expects the pricing power and occupancy gains to persist through another full year.
Includes the remaining tranches of the Outpatient Medical (OM) portfolio sale. The capital recycling program is not finished.
Key Questions
Integration Bandwidth
With $13.9 billion deployed in Q4—more than double the volume of many prior full years—how is the operational infrastructure handling the integration of Barchester and HC-One simultaneously?
UK Exposure Risks
The Q4 acquisitions heavily weight the new growth into the UK market. How are you hedging the increased exposure to GBP currency fluctuations and potential UK labor regulation changes?
Private Funds Trajectory
With Fund I closed at $2.5B, what is the scaling ambition for the Investment Management business? Should we expect this to become a reportable segment with material fee income in FY26?